1. Home
  2. HUN vs DNLI Comparison

HUN vs DNLI Comparison

Compare HUN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HUN

Huntsman Corporation

BUY

Current Price

$13.16

Market Cap

2.8B

Sector

Industrials

ML Signal

BUY

Logo Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc.

HOLD

Current Price

$22.34

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUN
DNLI
Founded
1970
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.0B
IPO Year
2004
2017

Fundamental Metrics

Financial Performance
Metric
HUN
DNLI
Price
$13.16
$22.34
Analyst Decision
Hold
Strong Buy
Analyst Count
11
14
Target Price
$12.09
$34.33
AVG Volume (30 Days)
4.0M
1.7M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
2.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,683,000,000.00
N/A
Revenue This Year
$3.08
N/A
Revenue Next Year
$5.27
$408.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.30
$12.58
52 Week High
$16.09
$23.77

Technical Indicators

Market Signals
Indicator
HUN
DNLI
Relative Strength Index (RSI) 40.34 65.75
Support Level $13.13 $17.77
Resistance Level $13.94 $23.62
Average True Range (ATR) 0.68 1.05
MACD -0.06 0.27
Stochastic Oscillator 20.79 96.62

Price Performance

Historical Comparison
HUN
DNLI

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Share on Social Networks: